ImClone Systems Inc (formerly IMCL)

[biophud]

Any updates on the LLY/Imclone integration? The article below got me thinking about what LLY is doing. Have there been any major changes (hirings, firings, etc.)? In addition to the current clinical pipeline, I think that there is an opportunity for LLY to provide IMCL with new targets so that IMCL can use its core competency in developing antagonists antibodies to RTKs and other cell surface receptors. I hope that such a cross-talk and expansion of research projects is happening and I hope that LLY is not cutting the IMCL R&D staff. From what I hear, the J&J purchase of Centocor (sp?) worked well, J&J left Centocor alone, and if spun off today Centocor would be much more than J&J's original purchace price.

http://finance.yahoo.com/news/Level-3-expands-services-to-apf-1047705565.html?x=0&.v=1